Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings

GSK and CureVac restructure collaboration into new licensing agreement

CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced

Bayer Q1 2024 net income drops 8.2% to € 2 billion

EBITDA before special items falls 1.3 percent to € 4.41 billion

Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall

Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims

Bayer aims to enhance performance and regain strategic flexibility by 2026

Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

VP Dhankhar emphasizes need for ethical standards in the medical profession at APICON-2024

The Vice President also highlighted the importance of preventive healthcare and fitness

Natco Pharma and Breckenridge dismissed from antitrust lawsuit

Intermountain Health files complain against Dr. Reddy’s and others

Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation

Mixed prospects for Merck lawsuit against US federal government, says GlobalData

The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past